Drug Discovery and Development: Antares Pharma, Inc. (AIS)

• Publication date: August 2012
• Report size: 39 pages

This report is a source for data, analysis and actionable intelligence on the Antares Pharma, Inc. portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover data on product description, func...

This report is a source for data, analysis and actionable intelligence on the Antares Pharma, Inc. portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover data on product description, function, technology, indication, and application. The report is also supplemented with a detailed industry player profile and data on clinical trials, wherever applicable.

Scope of the Research

- Detailed industry player profile with data on business description, key industry player facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the new product development, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional data on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with data on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, industry ing and sales strategies.
- Exploit Merger and Acquisition opportunities by identifying industry players with the most innovative pipeline.
- Develop successful market-entry strategies .
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ new product development through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

Drug Delivery Technology Industry in the United States

Data table of Contents
Data table of Contents 2
List of Tables 3
List of Figures 3
Antares Pharma, Inc. - Business Overview 4
Key Facts 4
Antares Pharma, Inc. - Major Products and Services 5
Antares Pharma, Inc. Pipeline Products by Equipment Type 6
Antares Pharma, Inc. Pipeline Products by Development Stage 8
Antares Pharma, Inc. Pipeline Products by Therapy Area 10
Pen 1 12
Product Status 12
Product Description 12
Pen 2 12
Product Status 12
Product Description 12
VIBEX MTX 12
Product Status 12
Product Description 13
Antares Pharma, Inc. - Top Competitors 14
Antares Pharma, Inc. - Key Executives 15
Antares Pharma, Inc. - Key Employee Biographies 16
Antares Pharma, Inc. - Operations and Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
March 14, 2011: Antares Pharma Reports Net Loss Of US$ 1.3m For Q4 2010 18
November 10, 2010: Antares Pharma Reports Total Sales s Of US$ 3.12 Mln For Q3 2010 18
November 03, 2010: Antares Pharma Receives Qualifying Therapeutic Discovery Project Grants For Anturol And VIBEX MTX Development Programs 18
September 17, 2010: Antares Pharma Announces Senior Management Changes 19
August 12, 2010: Antares Pharma Reports Net Loss Of US$ 1.5 Mln For Q2 2010 19
May 13, 2010: Antares Reports Net Loss Of US$ 1.6 Mln For Q1 2010 19
May 13, 2010: Antares Reports Net Loss Of US$ 1.6 Mln For Q1 2010 20
March 23, 2010: Antares Reports Net Loss Of US$ 2.4 Mln For Q4 2009 20
March 23, 2010: Antares Pharma Reports Net Loss Of US$ 2.4 Mln In Q4 2009 20
March 02, 2010: Antares Pharma, Inc. (Antr) Announces Completion Of Patient Enrollment In Phase 3 Pivotal Trial Of Anturol(Tm) For The Treatment Of Overactive Bladder 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22


List of Tables

Antares Pharma, Inc., Major development 1
Antares Pharma, Inc. Key Pipeline Products by Equipment Type 1
Antares Pharma, Inc. Key Pipeline Products by Therapy Area 1
Antares Pharma, Inc. Key Pipeline Products by Development Stage 1
Antares Pharma, Inc. Key Pipeline Products by Trial Phase 1
Antares Pharma, Inc., Major development 4
Antares Pharma, Inc., Major Products and Services 5
Antares Pharma, Inc. Number of Pipeline Products by Equipment Type 6
Antares Pharma, Inc. Pipeline Products by Equipment Type 7
Antares Pharma, Inc. Number of Pipeline Products by Development Stage 8
Antares Pharma, Inc. Pipeline Products by Development Stage 9
Antares Pharma, Inc. Number of Pipeline Products by Therapy Area 10
Antares Pharma, Inc. Pipeline Products by Therapy Area 11
Pen 1 - Product Status 12
Pen 1 - Product Description 12
Pen 2 - Product Status 12
Pen 2 - Product Description 12
VIBEX MTX - Product Status 12
VIBEX MTX - Product Description 13
Antares Pharma, Inc., Key Executives 15
Antares Pharma, Inc., Key Employee Biographies 16
Antares Pharma, Inc., Other Locations 17
Antares Pharma, Inc., Subsidiaries 17


List of Figures

Antares Pharma, Inc. Pipeline Products by Equipment Type 6
Antares Pharma, Inc. Pipeline Products by Development Stage 8
Antares Pharma, Inc. Pipeline Products by Therapy Area 10

Companies mentioned West Pharmaceutical Services, Inc.
SHL Group
Ypsomed AG
November avax, Inc.
April icus Bioscience Inc
Acrux Limited
Watson Pharmaceuticals, Inc.
SkyePharma PLC
ALZA Corporation
Alkermes, Inc.